兄弟科技(002562.SZ)子公司碘帕醇注射液获批上市

Core Viewpoint - Brother Technology (002562.SZ) announced that its wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has received the drug registration certificate for Iohexol injection from the National Medical Products Administration, allowing for commercial sales in China [1] Group 1 - The Iohexol injection is primarily used for various types of imaging procedures, including cardiovascular, peripheral artery, venous, coronary, cerebral, urinary tract, spinal, and joint imaging, as well as CT enhancement [1] - The product is characterized by low viscosity and good safety, which are significant advantages in its application [1] - The approval for Iohexol injection marks a significant step for Brother Pharmaceutical in commercializing this product, enhancing its product line of iodine contrast agents and increasing its competitiveness in the contrast agent market [1]